ALK and neoplasm: For instance, EGFRL858R/exon19Δ predicts a high propensity of bone and pleura metastases in a group of treating naïve patients with lung adenocarcinoma in late IV stage, while tumour cells with ALK rearrangement are more prone to metastasize to the liver.25